Prognostification of ALL by Cytogenetics.
Srīnagar, India. In Indian J Hematol Blood Transfus, 30 Sep 2015
Some chromosomal abnormalities are associated with more favorable outcomes, such as high hyperdiploidy (51-65 chromosomes) and the ETV6-RUNX1 fusion.
Resistance in the Ribosome: RUNX1, pre-LSCs, and HSPCs.
United States. In Cell Stem Cell, 06 Sep 2015
(2015) show that loss-of-function mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal hematopoietic cells through increased stress resistance.
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
Bologna, Italy. In Clin Lymphoma Myeloma Leuk, Jun 2015
Mutations in genes other than BCR-ABL1 include ASXL1, TET2, RUNX1, DNMT3A, EZH2, and TP53 in chronic phase patients and RUNX1, ASXL1, IKZF1, WT1, TET2, NPM1, IDH1, IDH2, NRAS, KRAS, CBL, TP53, CDKN2A, RB1, and GATA-2 mutations in advanced phase patients.
Harnessing the Therapeutic Potential of Th17 Cells.
Arbīl, Iraq. In Mediators Inflamm, Dec 2014
For development, Th17 cells require activation of the transcription factors STAT3 and RORγt while RUNX1, c-Maf, and Aiolos are involved in changes of phenotype/functions.